For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study. Izanne Roos, M.B.Ch.B., Ph.D. and colleagues examined whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS in an observational cohort study. Participants had a history of relapsing-remitting MS treated with ocrelizumab or rituximab, a minimum follow-up of six months, and sufficient data to calculate the propensity score. The analysis included 710 patients treated with ocrelizumab and 186 treated with rituximab. The researchers found that the annualized rate of relapses ratio was higher in patients treated with rituximab versus ocrelizumab (rate...